BEAM Beam Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1745999 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY163.3%
TTM net income YoY74.1%
TTM EPS YoY80.0%
Revenue 3-yr CAGR21.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-267.7%
Net margin-73.0%
FCF margin-271.6%
EBITDA margin-252.6%
Returns
ROE-11.1%
ROA-8.3%
ROIC (approx.)-40.2%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets24.9%
Debt / equity0.11x
Current ratio13.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.63x
Accruals ratio21.8%
Payout ratio—
Capex / revenue6.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $139.74M | $63.52M |
| R&D expense | $409.62M | $367.56M |
| SG&A expense | $113.82M | $111.53M |
| Operating income | -$383.69M | -$415.57M |
| Pretax income | -$79.99M | -$376.70M |
| Income tax | $0 | $39,000 |
| Net income | -$79.99M | -$376.74M |
| EBITDA | -$361.40M | -$393.64M |
| EPS (basic) | -0.81 | -4.58 |
| EPS (diluted) | -0.81 | -4.58 |
| Weighted avg. shares (diluted) | 98.91M | 82.31M |
| Balance sheet | ||
| Cash & equivalents | $294.94M | $290.11M |
| Short-term investments | $950.27M | $568.77M |
| Current assets | $1.27B | $878.15M |
| PP&E, net | $104.50M | $111.41M |
| Total assets | $1.48B | $1.10B |
| Current liabilities | $96.94M | $182.07M |
| Total liabilities | $242.82M | $370.28M |
| Shareholders' equity | $1.24B | $733.54M |
| Shares outstanding | 101.75M | 83.63M |
| Cash flow statement | ||
| Operating cash flow | -$345.10M | -$347.25M |
| Capital expenditure | $14.95M | $8.95M |
| Free cash flow | -$360.05M | -$356.19M |
| Investing cash flow | -$121.44M | $185.01M |
| Financing cash flow | $478.05M | $7.74M |
| Depreciation & amortization | $22.29M | $21.93M |
| Stock-based compensation | $94.24M | $120.66M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.